Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International PLC : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Endo International plc - ENDP

09/15/2017 | 01:33pm EDT

NEW YORK, NY / ACCESSWIRE / September 15, 2017 / Pomerantz LLP is investigating claims on behalf of investors of Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Endo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On May 15, 2017, post-market, Reuters reported that Orange County, New York had sued Endo, along with other pharmaceutical companies, accusing the Company of engaging in fraudulent marketing that downplayed the risks of prescription opioid painkillers. On this news, Endo's share price fell $0.94, or 6.98%, over the following two trading days to close at $12.52 on May 17, 2017.

On June 8, 2017, the U.S. Food and Drug Administration instructed Endo to pull its opioid painkiller Opana ER from the U.S. market, citing Opana's "high risk of abuse and potential to help spread HIV and hepatitis C." On this news, Endo's share price fell $2.29 or 16.62%, to close at $11.49 on June 19, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


© Accesswire 2017
All news about ENDO INTERNATIONAL PLC
10/22ENDO INTERNATIONAL : Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Ana..
PR
10/21STRIDES PHARMA SCIENCE : Completes Acquisition of US-Based Endo International's Assets for..
MT
10/05ENDO INTERNATIONAL : to Announce Third Quarter 2021 Financial Results
PR
09/30ENDO INTERNATIONAL : California judge questions counties' opioid case against drugmakers a..
RE
09/30ENDO INTERNATIONAL : Says Research Shows Prescription Drug Xiaflex May be Appropriate to T..
MT
09/30ENDO INTERNATIONAL : California judge questions counties' opioid case against drugmakers a..
RE
09/30ENDO INTERNATIONAL : Presents New Investigational Collagenase Clostridium Histolyticum (CC..
AQ
09/30Endo International plc Presents New Investigational Collagenase Clostridium Histolyticu..
CI
09/28ENDO INTERNATIONAL : Reaches Agreement in Principle to Settle Louisiana Governmental Opioi..
PR
09/28Drug distributors strike 1st opioid settlement with Native American tribe for $75 mln
RE
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 787 M - -
Net income 2021 39,5 M - -
Net Debt 2021 6 718 M - -
P/E ratio 2021 7,48x
Yield 2021 -
Capitalization 1 065 M 1 065 M -
EV / Sales 2021 2,79x
EV / Sales 2022 2,68x
Nbr of Employees 3 397
Free-Float 98,5%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 4,56 $
Average target price 6,57 $
Spread / Average Target 44,1%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations